<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539473</url>
  </required_header>
  <id_info>
    <org_study_id>1986-032</org_study_id>
    <secondary_id>TR701-105</secondary_id>
    <nct_id>NCT01539473</nct_id>
  </id_info>
  <brief_title>A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge</brief_title>
  <official_title>A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered
      with tyramine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to
      determine the effect of 200 mg oral TR-701 FA on SBP response when administered with tyramine
      in healthy adult male and female volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>14 days</time_frame>
    <description>To assess tyramine dose required to cause increase of 30 mmHg in systolic blood pressure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TR-701 FA with Tyramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR-701 FA 200 oral with Tyramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-controlled with Tyramine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-controlled with Tyramine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA with Tyramine</intervention_name>
    <description>TR-701 FA 200 mg oral and Tyramine</description>
    <arm_group_label>TR-701 FA with Tyramine</arm_group_label>
    <other_name>Tedizolid Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-controlled withTyramine</intervention_name>
    <description>Placebo-controlled and Tyramine</description>
    <arm_group_label>Placebo-controlled with Tyramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18 to 45 years of age, inclusive

          -  Body mass index between 19 kg/m2 and 31 kg/m2, inclusive

          -  Healthy subjects with no clinically significant abnormalities identified by a detailed
             medical history,

        Exclusion Criteria:

          -  Systolic blood pressure &gt;130 mmHg or &lt;90 mmHg measured after 10 minutes in the supine
             position at Screening or at admission to the study center

          -  Heart rate &gt;90 bpm or &lt;45 bpm measured after 10 minutes in the supine position

          -  Electrocardiogram (ECG) finding of QTc interval &gt;500 msec, or other clinically
             significant ECG abnormality at the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe G Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator Site 001</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Tyramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

